Novo blames pharma middlemen over Wegovy pricing: Bloomberg News
Amid mounting criticism over its pricing strategy for its popular weight loss drugs Ozempic and Wegovy, Novo Nordisk (NVO) said that the company retains only 60% of the products’ list price after payments to pharma middlemen,